礼来公司投资8600万美元用于中药癌症疗法研发

仲夏秋夜云

礼来公司投资8600万美元用于中药癌症疗法研发
由李嘉诚投资的Hutchison China MediTech公司和礼来公司达成了一项关于研发传统中药抗癌药物fruquintinib的研发协议。礼来公司将投资8600万美元在该项目上。Fruquintinib是一种VEGFR1、2、3抑制物，有望治疗多种癌症，该药物目前处于临床二期研究。


最近几年，许多跨国药企都对中国的中药研究表示出了浓厚的兴趣。如GSK在中国设立专门研究中药的研究机构，强生在感染领域也进行了类似的投资，这都表现出中药在今后药物研发中光明的前景。（生物谷Bioon.com）


详细英文报道：


Hutchison China MediTech, backed by Hong Kong billionaire Li Ka-Shing and best known as Chi-Med, says its R&D group has found another major league pharma partner for one of its programs based on its work on traditional Chinese medicines. Eli Lilly ($LLY) has signed on to collaborate on fruquintinib, committing to a package of $86.5 million in fees and milestones to partner on a tumor treatment which was put up on the deal table earlier this year.


Currently in a mid-stage study and cleared for Phase II/III by China's FDA, fruquintinib is a VEGFR 1, 2 and 3 inhibitor with potential to treat a variety of tumor types. Chi-Med will pay for the bulk of the development work and stands to gain a royalty stream on any approvals.


Chi-Med CEO Christian Hogg told Bloomberg last spring that the company believes this program has some strong potential for colorectal, lung, breast and gastric cancers, which overlaps some of Lilly's work in the oncology field. Guillaume van Renterghem, an analyst at UBS AG, put peak potential sales at $650 million, according to the business news service.


Chinese botanicals have drawn some intense interest from major players who have been carefully focused on big emerging markets like China. GlaxoSmithKline ($GSK) recently set up a dedicated research unit devoted to traditional meds in China. Just last week, HCM landed a $6 million milestone on its partnership with J&J ($JNJ) on inflammation/immunology. And there's another $90 million in potential payments to go.


"In Lilly's emerging markets business, we are focused on providing patients with innovative medicines from our own pipeline and through collaborations with respected science-based companies such as HMP," said Jacques Tapiero, Lilly's president of emerging markets. "Together, we are committed to help meet the medical needs of oncology patients in China."

lunmulunmu

看看               

yyylggglll

但愿有好的结果。